Kenvue Recovery Post Regulatory Concerns

about 1 month ago

Valerie Teitel

"Kenview is the maker of Tylenol. And it fell yesterday on reports of the Trump administration linking its use in pregnancy to autism. But city analysts noting the lack of new evidence and the limited judicial risk means that perhaps there is some upside risk in the stock."

Kenvue, the Tylenol maker, saw a sharp decline due to regulatory concerns. However, with no new evidence to support the fears and limited judicial risk, investor sentiment appears to be turning, suggesting potential upside in the near term.

Related Stocks